SEC Form 4 · accession 0001203311-18-000085
SEATTLE GENETICS INC /WA · SGEN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Roger D Dansey
Officer — Chief Medical Officer
Period of report
Sep 7, 2018
Accepted (ET)
Sep 11, 2018 · 7:29 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001060736
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2,F3 | Sep 7, 2018 | A | 5,898 | $0.00 | A | 77,241 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (right to buy)F4 | $77.45 | Sep 7, 2018 | A | 14,010 | A | — | Sep 7, 2028 | Common Stock | 14,010 | 14,010 | D |
Explanation of responses
- F1These shares represent restricted stock units and will be settled in common stock upon vesting.
- F2Shares shall vest at a rate of 25% on each anniversary of the grant date until all shares are fully vested four years from the grant date.
- F3Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting.
- F4Shares shall vest at a rate of 25% one year from the grant date and monthly thereafter until all shares are fully vested four years from the grant date.